Tubulis, a Planegg-Martinsried, Munich, Germany-based cancer drug development company, raised €308 million in a Series C fundraising round led by Venrock Healthcare Capital Partners with participation from Wellington Management, Ascenta Capital, and others.
More on SiliconCanals →
